AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
dichlorphenamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 864 | 120-97-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 9.36 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| S (Water solubility) | 0.10 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK1,MAPK10,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK3,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ZAP70 | 52 | |||
| kinase-selectivity-class | AXL,GRK2,MAP2K6,MAPK7,MAPKAPK3,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,TEK,UHMK1,ZAP70 | 13 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 22, 1958 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Wrong technique in product usage process | 185.08 | 39.00 | 62 | 1456 | 71509 | 90555420 |
| Paraesthesia | 180.25 | 39.00 | 86 | 1432 | 250240 | 90376689 |
| Disease recurrence | 139.78 | 39.00 | 43 | 1475 | 37610 | 90589319 |
| Feeling abnormal | 94.74 | 39.00 | 49 | 1469 | 167186 | 90459743 |
| Blood potassium decreased | 79.83 | 39.00 | 30 | 1488 | 47697 | 90579232 |
| Dysgeusia | 73.49 | 39.00 | 29 | 1489 | 52531 | 90574398 |
| Muscular weakness | 64.28 | 39.00 | 41 | 1477 | 206625 | 90420304 |
| Confusional state | 39.72 | 39.00 | 40 | 1478 | 386165 | 90240764 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Disease recurrence | 169.22 | 53.95 | 49 | 804 | 29629 | 42590853 |
| Paraesthesia | 154.81 | 53.95 | 57 | 796 | 73402 | 42547080 |
| Muscular weakness | 73.80 | 53.95 | 35 | 818 | 83463 | 42537019 |
| Wrong technique in product usage process | 71.04 | 53.95 | 28 | 825 | 42607 | 42577875 |
| Blood potassium decreased | 58.48 | 53.95 | 20 | 833 | 20364 | 42600118 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Disease recurrence | 259.99 | 43.19 | 75 | 1548 | 60709 | 110526967 |
| Paraesthesia | 214.43 | 43.19 | 96 | 1527 | 276425 | 110311251 |
| Blood potassium decreased | 98.66 | 43.19 | 35 | 1588 | 54079 | 110533597 |
| Muscular weakness | 87.89 | 43.19 | 51 | 1572 | 248417 | 110339259 |
| Feeling abnormal | 82.77 | 43.19 | 44 | 1579 | 180667 | 110407009 |
| Wrong technique in product usage process | 82.38 | 43.19 | 35 | 1588 | 87313 | 110500363 |
| Dysgeusia | 75.93 | 43.19 | 31 | 1592 | 69954 | 110517722 |
| Fatigue | 48.64 | 43.19 | 73 | 1550 | 1215885 | 109371791 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | S01EC02 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Carbonic anhydrase inhibitors |
| FDA CS | M0020790 | Sulfonamides |
| FDA MoA | N0000000235 | Carbonic Anhydrase Inhibitors |
| FDA EPC | N0000175517 | Carbonic Anhydrase Inhibitor |
| MeSH PA | D002257 | Carbonic Anhydrase Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| CHEBI has role | CHEBI:23018 | EC 4.2.1.1 (carbonic anhydrase) inhibitor |
| CHEBI has role | CHEBI:39456 | antiglaucoma drug |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
Related Drugs by ATC class:
S01EC Carbonic anhydrase inhibitors 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Open-angle glaucoma | indication | 84494001 | DOID:1067 |
| Secondary glaucoma | indication | 95717004 | |
| Angle-closure glaucoma | indication | 392291006 | DOID:13550 |
| Malignant glaucoma | off-label use | 10100008 | |
| Renal tubular acidosis | contraindication | 1776003 | DOID:14219 |
| Respiratory acidosis | contraindication | 12326000 | |
| Hyperkalemia | contraindication | 14140009 | |
| Metabolic acidosis, normal anion gap, acidifying salts | contraindication | 18104000 | |
| Diabetes mellitus type 2 | contraindication | 44054006 | DOID:9352 |
| Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Decreased respiratory function | contraindication | 80954004 | |
| Hyponatremia | contraindication | 89627008 | |
| Gout | contraindication | 90560007 | DOID:13189 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Disorder of electrolytes | contraindication | 237840007 | |
| Primary adrenocortical insufficiency | contraindication | 373662000 | |
| Recurrent Calcium Renal Calculi | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.51 | acidic |
| pKa2 | 9.19 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Carbonic anhydrase 12 | Enzyme | INHIBITOR | Ki | 7.30 | WOMBAT-PK | CHEMBL | |||
| Carbonic anhydrase 1 | Enzyme | INHIBITOR | IC50 | 8.30 | WOMBAT-PK | CHEMBL | |||
| Carbonic anhydrase 4 | Enzyme | INHIBITOR | Ki | 7.02 | CHEMBL | CHEMBL | |||
| Carbonic anhydrase 2 | Enzyme | INHIBITOR | Ki | 7.42 | WOMBAT-PK | CHEMBL | |||
| Carbonic anhydrase 5B, mitochondrial | Enzyme | INHIBITOR | Ki | 7.68 | WOMBAT-PK | ||||
| Carbonic anhydrase 7 | Enzyme | INHIBITOR | Ki | 7.58 | WOMBAT-PK | ||||
| Carbonic anhydrase 6 | Enzyme | Ki | 7.10 | CHEMBL | |||||
| Carbonic anhydrase 14 | Enzyme | Ki | 6.46 | CHEMBL | |||||
| Carbonic anhydrase 13 | Enzyme | Ki | 7.64 | CHEMBL | |||||
| Cytochrome P450 2C9 | Enzyme | EC50 | 5.60 | WOMBAT-PK | |||||
| Carbonic anhydrase 9 | Enzyme | INHIBITOR | Ki | 7.30 | WOMBAT-PK | ||||
| Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 6.20 | WOMBAT-PK | |||||
| Carbonic anhydrase | Enzyme | Ki | 6.42 | WOMBAT-PK | |||||
| Carbonic anhydrase 13 | Enzyme | Ki | 7.64 | CHEMBL | |||||
| Carbonic anhydrase 4 | Enzyme | Ki | 6.42 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 6.82 | CHEMBL | |||||
| Carbonic anhydrase 15 | Enzyme | Ki | 7.02 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 6.99 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 7.42 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 6.95 | CHEMBL | |||||
| Alpha carbonic anhydrase | Enzyme | Ki | 6.37 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 7.10 | CHEMBL | |||||
| Carbonic anhydrase 2 | Enzyme | Ki | 5.92 | CHEMBL | |||||
| Astrosclerin-3 | Enzyme | Ki | 7.21 | CHEMBL | |||||
| Beta-carbonic anhydrase 1 | Enzyme | Ki | 6.06 | CHEMBL | |||||
| Delta carbonic anhydrase | Enzyme | Ki | 6.34 | CHEMBL | |||||
| Carbonic anhydrase 2 | Enzyme | Ki | 5.70 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 6.20 | CHEMBL | |||||
| Carbonic anhydrase, alpha family | Enzyme | Ki | 7.61 | CHEMBL | |||||
| Carbonate dehydratase | Enzyme | Ki | 8.07 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017928 | VUID |
| N0000146279 | NUI |
| D00518 | KEGG_DRUG |
| 3353 | RXNORM |
| 4017928 | VANDF |
| C0012086 | UMLSCUI |
| CHEBI:101085 | CHEBI |
| I7A | PDB_CHEM_ID |
| CHEMBL17 | ChEMBL_ID |
| DB01144 | DRUGBANK_ID |
| 639 | INN_ID |
| VVJ6673MHY | UNII |
| 3038 | PUBCHEM_CID |
| 364734 | MMSL |
| 4581 | MMSL |
| d00639 | MMSL |
| 002288 | NDDF |
| 19583005 | SNOMEDCT_US |
| 387111009 | SNOMEDCT_US |
| D004005 | MESH_DESCRIPTOR_UI |
| 6807 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Dichlorphenamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-676 | TABLET | 50 mg | ORAL | ANDA | 26 sections |
| Dichlorphenamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16571-242 | TABLET | 50 mg | ORAL | ANDA | 26 sections |
| ORMALVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70709-085 | TABLET | 50 mg | ORAL | ANDA | 26 sections |
| ORMALVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70709-085 | TABLET | 50 mg | ORAL | ANDA | 26 sections |
| Keveyis | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71090-001 | TABLET | 50 mg | ORAL | NDA | 26 sections |
| Keveyis | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72065-001 | TABLET | 50 mg | ORAL | NDA | 25 sections |